Sunitinib Dr.Reddy's

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Sunitinib malate 50.1mg equivalent to Sunitinib 37.5 mg

Available from:

Dr Reddy's New Zealand Limited

Dosage:

37.5 mg

Pharmaceutical form:

Capsule

Composition:

Active: Sunitinib malate 50.1mg equivalent to Sunitinib 37.5 mg Excipient: Croscarmellose sodium Gelatin Iron oxide yellow Magnesium stearate Mannitol Povidone Sodium laurilsulfate Titanium dioxide Water

Prescription type:

Prescription

Therapeutic indications:

Treatment of advanced renal cell carcinoma Treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance Treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET)

Product summary:

Package - Contents - Shelf Life: Blister pack, Polyvinyl chloride/Aclar aluminium blister package within a carton-cardboard - 28 capsules - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, High-density polyethylene bottle and a plastic CRC cap with pulp liner - 28 capsules - 24 months from date of manufacture stored at or below 25°C

Authorization date:

2021-05-12